Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Cytek Biosciences, Inc. stock logo
CTKB
Cytek Biosciences
$3.52
-5.9%
$4.49
$3.27
$7.63
$450.90M1.41721,262 shs950,822 shs
Standard BioTools Inc. stock logo
LAB
Standard BioTools
$1.10
-5.2%
$1.20
$0.97
$2.94
$439.62M1.542.31 million shs1.54 million shs
Transcat, Inc. stock logo
TRNS
Transcat
$77.24
+0.9%
$76.40
$67.56
$147.12
$719.03M0.6771,867 shs138,186 shs
10x Genomics, Inc. stock logo
TXG
10x Genomics
$7.70
-11.2%
$10.57
$6.78
$36.46
$941.73M2.012.16 million shs3.91 million shs
These 7 Stocks Will Be Magnificent in 2025 Cover

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Cytek Biosciences, Inc. stock logo
CTKB
Cytek Biosciences
-5.88%-5.38%-17.76%-48.39%-43.68%
Standard BioTools Inc. stock logo
LAB
Standard BioTools
-5.17%+2.80%-3.51%-32.52%-61.27%
Transcat, Inc. stock logo
TRNS
Transcat
+0.91%+6.14%+8.74%-24.72%-29.88%
10x Genomics, Inc. stock logo
TXG
10x Genomics
-11.19%-3.39%-28.77%-50.58%-78.19%
Remove Ads
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Cytek Biosciences, Inc. stock logo
CTKB
Cytek Biosciences
1.5748 of 5 stars
3.22.00.00.02.91.70.0
Standard BioTools Inc. stock logo
LAB
Standard BioTools
2.6324 of 5 stars
3.32.00.00.02.74.20.6
Transcat, Inc. stock logo
TRNS
Transcat
2.4137 of 5 stars
3.21.00.00.02.73.31.3
10x Genomics, Inc. stock logo
TXG
10x Genomics
4.5819 of 5 stars
4.23.00.04.82.14.20.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Cytek Biosciences, Inc. stock logo
CTKB
Cytek Biosciences
2.33
Hold$6.4282.29% Upside
Standard BioTools Inc. stock logo
LAB
Standard BioTools
2.50
Moderate Buy$2.50127.27% Upside
Transcat, Inc. stock logo
TRNS
Transcat
2.40
Hold$111.5044.36% Upside
10x Genomics, Inc. stock logo
TXG
10x Genomics
2.35
Hold$19.79156.96% Upside

Current Analyst Ratings Breakdown

Latest LAB, TXG, TRNS, and CTKB Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
4/10/2025
10x Genomics, Inc. stock logo
TXG
10x Genomics
Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOverweight ➝ Overweight$15.00 ➝ $12.00
4/8/2025
10x Genomics, Inc. stock logo
TXG
10x Genomics
Weiss Ratings
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingSell (E+) ➝ Sell (E+)
3/22/2025
10x Genomics, Inc. stock logo
TXG
10x Genomics
Weiss Ratings
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingSell (E+) ➝ Sell (E+)
3/19/2025
Cytek Biosciences, Inc. stock logo
CTKB
Cytek Biosciences
Stephens
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$6.00 ➝ $6.00
3/7/2025
10x Genomics, Inc. stock logo
TXG
10x Genomics
Weiss Ratings
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingSell (E+) ➝ Sell (E+)
3/4/2025
Cytek Biosciences, Inc. stock logo
CTKB
Cytek Biosciences
Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOverweight ➝ Overweight$8.50 ➝ $8.00
3/4/2025
10x Genomics, Inc. stock logo
TXG
10x Genomics
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$20.00 ➝ $15.00
2/27/2025
Standard BioTools Inc. stock logo
LAB
Standard BioTools
KeyCorp
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeOverweight ➝ Sector Weight
2/19/2025
10x Genomics, Inc. stock logo
TXG
10x Genomics
Weiss Ratings
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingSell (E+) ➝ Sell (E+)
2/14/2025
10x Genomics, Inc. stock logo
TXG
10x Genomics
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOverweight ➝ Overweight$28.00 ➝ $26.00
2/13/2025
10x Genomics, Inc. stock logo
TXG
10x Genomics
Leerink Partnrs
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeStrong-Buy ➝ Hold
(Data available from 4/11/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Cytek Biosciences, Inc. stock logo
CTKB
Cytek Biosciences
$200.45M2.25$0.02 per share206.16$2.90 per share1.21
Standard BioTools Inc. stock logo
LAB
Standard BioTools
$174.43M2.39N/AN/A($1.85) per share-0.59
Transcat, Inc. stock logo
TRNS
Transcat
$272.20M2.64$2.85 per share27.14$30.19 per share2.56
10x Genomics, Inc. stock logo
TXG
10x Genomics
$610.79M1.54N/AN/A$5.81 per share1.33
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Cytek Biosciences, Inc. stock logo
CTKB
Cytek Biosciences
-$12.15M-$0.05N/AN/A-5.05%-2.58%-2.05%5/6/2025 (Estimated)
Standard BioTools Inc. stock logo
LAB
Standard BioTools
-$74.66M-$0.55N/AN/AN/A-79.92%-27.05%-15.52%5/6/2025 (Estimated)
Transcat, Inc. stock logo
TRNS
Transcat
$13.65M$1.8541.7529.37N/A6.22%7.23%5.67%5/19/2025 (Estimated)
10x Genomics, Inc. stock logo
TXG
10x Genomics
-$182.63M-$1.52N/AN/AN/A-29.90%-25.40%-19.69%4/29/2025 (Estimated)

Latest LAB, TXG, TRNS, and CTKB Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
4/29/2025Q1 2025
10x Genomics, Inc. stock logo
TXG
10x Genomics
-$0.46N/AN/AN/A$131.91 millionN/A
2/12/2025Q4 2024
10x Genomics, Inc. stock logo
TXG
10x Genomics
-$0.32-$0.40-$0.08-$0.40N/AN/A
1/27/2025Q3 2025
Transcat, Inc. stock logo
TRNS
Transcat
$0.38$0.45+$0.07$0.25$70.30 millionN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Cytek Biosciences, Inc. stock logo
CTKB
Cytek Biosciences
N/AN/AN/AN/AN/A
Standard BioTools Inc. stock logo
LAB
Standard BioTools
N/AN/AN/AN/AN/A
Transcat, Inc. stock logo
TRNS
Transcat
N/AN/AN/AN/AN/A
10x Genomics, Inc. stock logo
TXG
10x Genomics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Cytek Biosciences, Inc. stock logo
CTKB
Cytek Biosciences
N/A
6.21
5.47
Standard BioTools Inc. stock logo
LAB
Standard BioTools
N/A
3.76
3.41
Transcat, Inc. stock logo
TRNS
Transcat
0.14
2.42
1.98
10x Genomics, Inc. stock logo
TXG
10x Genomics
N/A
4.97
4.26

Institutional Ownership

CompanyInstitutional Ownership
Cytek Biosciences, Inc. stock logo
CTKB
Cytek Biosciences
69.46%
Standard BioTools Inc. stock logo
LAB
Standard BioTools
53.74%
Transcat, Inc. stock logo
TRNS
Transcat
98.34%
10x Genomics, Inc. stock logo
TXG
10x Genomics
84.68%

Insider Ownership

CompanyInsider Ownership
Cytek Biosciences, Inc. stock logo
CTKB
Cytek Biosciences
9.60%
Standard BioTools Inc. stock logo
LAB
Standard BioTools
53.10%
Transcat, Inc. stock logo
TRNS
Transcat
2.30%
10x Genomics, Inc. stock logo
TXG
10x Genomics
10.03%
CompanyEmployeesShares OutstandingFree FloatOptionable
Cytek Biosciences, Inc. stock logo
CTKB
Cytek Biosciences
500128.10 million116.45 millionOptionable
Standard BioTools Inc. stock logo
LAB
Standard BioTools
620378.99 million174.59 millionOptionable
Transcat, Inc. stock logo
TRNS
Transcat
9209.31 million9.10 millionOptionable
10x Genomics, Inc. stock logo
TXG
10x Genomics
1,240122.30 million108.91 millionOptionable

Recent News About These Companies

Barclays Reaffirms Their Buy Rating on 10x Genomics (TXG)
10x Genomics price target lowered to $12 from $15 at Barclays

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Cytek Biosciences stock logo

Cytek Biosciences NASDAQ:CTKB

$3.52 -0.22 (-5.88%)
Closing price 04/10/2025 04:00 PM Eastern
Extended Trading
$3.52 +0.00 (+0.14%)
As of 04/10/2025 04:20 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Cytek Biosciences, Inc., a cell analysis solutions company, provides cell analysis tools that facilitates scientific advances in biomedical research and clinical applications. It offers aurora and northern lights systems, which are spectrum flow cytometers that delivers cell analysis by utilizing the fluorescence signatures from multiple lasers to distinguish fluorescent tags on single cells; and aurora cell sorter system that leverages full spectrum profiling technology to further broaden potential applications across cell analysis; aurora CS systems; amnis imagestream imaging flow cytometers; guava muse cell analyzers; guava easycyte flow cytometers; and orion reagent cocktail preparation systems. The company also provides reagents and kits, including cFluor reagents that are fluorochrome conjugated antibodies used to identify cells of interest for analysis on its instruments, as well as 25-color immunoprofiling assay that provides turnkey solutions for identifying major human immune subpopulations for TBNK cells, monocytes, dendritic cells, and basophils. In addition, it offers automated micro-sampling system and automated sample loader system, an automated loaders to integrate seamlessly into the aurora and northern lights systems; SpectroFlo software that provides intuitive workflow from quality control to data analysis for aurora and northern lights systems; and customer support tools. The company serves pharmaceutical and biopharma companies, academic research centers, and clinical research organizations. It distributes its products through direct sales force and support organizations in North America, Europe, China, and the Asia-Pacific regions; and through distributors or sales agents in European, Latin American, and the Middle Eastern countries. The company was formerly known as Cytoville, Inc. and changed its name to Cytek Biosciences, Inc. in August 2015. Cytek Biosciences, Inc. was founded in 1992 and is headquartered in Fremont, California.

Standard BioTools stock logo

Standard BioTools NASDAQ:LAB

$1.10 -0.06 (-5.17%)
Closing price 04/10/2025 04:00 PM Eastern
Extended Trading
$1.16 +0.06 (+5.91%)
As of 04/10/2025 07:09 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Standard BioTools Inc., together with its subsidiaries, provides instruments, consumables, reagents, and software services for researchers and clinical laboratories in the Americas, Europe, the Middle East, Africa, and the Asia pacific. It operates through two segments: Proteomics and Genomics. The company offers analytical systems, such as CyTOF XT System, a CyTOF XT mass cytometry system performs automated high-parameter single-cell analysis using antibodies conjugated to metal isotopes; and Hyperion XTi imaging system, a spatial biology instrument. It also provides genomics, such as X9 Real-Time PCR System, a real-time PCR analytical instrument including pre-processing steps for microfluidics-based workflows using (integrated fluidic circuit) IFCs; and IFC Controllers, a controller which is designed to work with IFC formats. In addition, the company offers analytical instruments comprising Biomark HD system, a real-time PCR analytical instrument for microfluidics-based workflows using prepared IFCs. It sells its products to academic research institutions; translational research and medicine centers; cancer centers; clinical research laboratories; biopharmaceutical, biotechnology, and plant and animal research companies; and contract research organizations. It has license agreements with California Institute of Technology, Harvard University, and Caliper Life Sciences, Inc. The company was formerly known as Fluidigm Corporation and changed its name to Standard BioTools Inc. in April 2022. Fluidigm Corporation was incorporated in 1999 and is headquartered in South San Francisco, California.

Transcat stock logo

Transcat NASDAQ:TRNS

$77.24 +0.70 (+0.91%)
Closing price 04/10/2025 04:00 PM Eastern
Extended Trading
$77.26 +0.02 (+0.03%)
As of 04/10/2025 07:13 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Transcat, Inc. provides calibration and laboratory instrument services in the United States, Canada, and internationally. It operates through two segments: Service and Distribution. The Service segment offers calibration, repair, inspection, analytical qualification, preventative maintenance, consulting, and other related services. This segment also provides CalTrak, a proprietary document and asset management system that is used to manage the workflow of its calibration service centers and customers' assets; and Compliance, Control and Cost, an online customer portal that provides its customers with web-based asset management capability, as well as a safe and secure off-site archive of calibration and other service records. The Distribution segment sells and rents test, measurement, and control instruments for customers' test and measurement instrumentation needs, as well as value added services, such as calibration/certification of equipment purchase, equipment rental, used equipment for sale, and equipment kitting. This segment markets and sells its products through website, digital and print advertising, proactive outbound sales, and an inbound call center. The company provides services and products to highly regulated industries, principally life science, which includes companies in the pharmaceutical, biotechnology, medical device, and other FDA-regulated industries; and additional industries, including aerospace and defense industrial manufacturing, energy and utilities, and other industries that require accuracy in processes and confirmation of the capabilities of their equipment. Transcat, Inc. was incorporated in 1964 and is headquartered in Rochester, New York.

10x Genomics stock logo

10x Genomics NASDAQ:TXG

$7.70 -0.97 (-11.19%)
Closing price 04/10/2025 04:00 PM Eastern
Extended Trading
$8.00 +0.30 (+3.90%)
As of 04/10/2025 07:39 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

10x Genomics, Inc., a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products. Its single cell solutions runs on its chromium instruments, which include single cell gene expression for measuring gene activity and networks on a cell-by-cell basis; single cell gene expression flex; single cell immune profiling used to study the immune system; single cell Assay for Transposase Accessible Chromati (ATAC) solution to understand the epigenetic state; and single cell multiome ATAC + gene expression which enables simultaneous interrogation of both the RNA and chromatin accessibility, using ATAC in a single cell. The company also provides Visium platform which enables researchers to understand the spatial positions of biological analytes within tissues at high resolution; and Xenium platform for in situ analysis. It serves various academic, government, biopharmaceutical, biotechnology, and other institutions. The company was formerly known as 10X Technologies, Inc. and changed its name to 10x Genomics, Inc. in November 2014. 10x Genomics, Inc. was incorporated in 2012 and is headquartered in Pleasanton, California.